IRIS
LODOLA, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.627
NA - Nord America 4.509
AS - Asia 2.279
SA - Sud America 232
AF - Africa 81
Continente sconosciuto - Info sul continente non disponibili 6
Totale 11.734
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.426
IT - Italia 1.206
CN - Cina 1.161
IE - Irlanda 823
FI - Finlandia 764
SG - Singapore 699
SE - Svezia 638
DE - Germania 468
UA - Ucraina 229
BR - Brasile 199
TR - Turchia 178
IN - India 94
FR - Francia 89
AT - Austria 80
GB - Regno Unito 78
CA - Canada 77
CI - Costa d'Avorio 69
RU - Federazione Russa 66
BE - Belgio 60
VN - Vietnam 34
CZ - Repubblica Ceca 29
HK - Hong Kong 24
ID - Indonesia 23
NL - Olanda 20
ES - Italia 15
AR - Argentina 13
RO - Romania 12
JP - Giappone 10
LT - Lituania 10
PK - Pakistan 10
PL - Polonia 7
EC - Ecuador 6
JO - Giordania 6
BD - Bangladesh 5
HR - Croazia 5
HU - Ungheria 5
VE - Venezuela 5
CH - Svizzera 4
CO - Colombia 4
EU - Europa 4
IL - Israele 4
NP - Nepal 4
DK - Danimarca 3
IQ - Iraq 3
IR - Iran 3
MX - Messico 3
NO - Norvegia 3
TH - Thailandia 3
TW - Taiwan 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BY - Bielorussia 2
CY - Cipro 2
DZ - Algeria 2
EG - Egitto 2
JM - Giamaica 2
MA - Marocco 2
MD - Moldavia 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
CL - Cile 1
CR - Costa Rica 1
EE - Estonia 1
KG - Kirghizistan 1
KR - Corea 1
LB - Libano 1
LU - Lussemburgo 1
MC - Monaco 1
MY - Malesia 1
NG - Nigeria 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
SA - Arabia Saudita 1
SC - Seychelles 1
SN - Senegal 1
TJ - Tagikistan 1
TM - Turkmenistan 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 11.734
Salva come PNG Salva come JPEG
Città #
Dublin 816
Chandler 742
Singapore 490
Parma 468
Santa Clara 440
Ann Arbor 398
Jacksonville 293
Ashburn 256
Dearborn 246
Beijing 243
Boardman 221
Nanjing 163
Izmir 160
Shanghai 152
Helsinki 138
Princeton 136
Wilmington 112
Munich 110
New York 109
Bremen 79
San Mateo 77
Abidjan 69
Milan 69
Shenyang 67
Vienna 63
Brussels 53
Toronto 53
Los Angeles 51
Kunming 49
Moscow 47
Jinan 46
Hebei 44
Nanchang 42
Council Bluffs 41
Hefei 39
Bologna 37
Des Moines 37
Seattle 37
Düsseldorf 35
Dong Ket 34
Modena 33
Jiaxing 32
Guangzhou 31
Woodbridge 30
Changsha 29
Bangalore 27
Fremont 27
Brescia 26
Jakarta 23
London 22
São Paulo 22
Nuremberg 21
Brno 20
Dallas 20
Pune 20
Tianjin 20
Norwalk 18
Hangzhou 17
Hong Kong 17
Ottawa 17
Zhengzhou 17
Ankara 14
Frankfurt am Main 14
Grafing 14
Rome 13
Prata Di Pordenone 12
Houston 11
Münster 11
Palermo 11
Verona 11
Belo Horizonte 10
Lubbock 10
Auburn Hills 9
Borås 9
Fairfield 9
Marseille 9
Naples 8
Taizhou 8
Weihai 8
Falls Church 7
Fuzhou 7
Hyderabad 7
Neviano degli Arduini 7
Ningbo 7
Piacenza 7
Redmond 7
Soliera 7
Tokyo 7
Washington 7
Ardea 6
Caorso 6
Follonica 6
Haikou 6
Madrid 6
Redwood City 6
Rimini 6
Sant'ilario D'enza 6
Vigevano 6
Amman 5
Amsterdam 5
Totale 7.576
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 219
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 171
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 170
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 169
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 160
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 147
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 146
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 139
inibitori eph-ephrin biodisponibili oralmente 132
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 130
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 121
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 121
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 120
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 119
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 118
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 116
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 115
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 114
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 114
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 110
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 109
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 109
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 109
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 104
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 103
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 101
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 101
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 100
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 100
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 96
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 96
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 96
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 95
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 95
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 94
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 93
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 93
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 93
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 90
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 90
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 89
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 88
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 87
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 87
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 86
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 86
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 85
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 85
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 84
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 84
Mechanism of inhibition of SARS-CoV-2 MprobyN3peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity 84
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 83
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 83
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 83
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 83
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 83
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 82
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 82
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 82
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 82
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 81
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 80
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 80
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 79
Irreversible EGFR inhibitor compounds with antiproliferative activity 79
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 79
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 79
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 78
Aromatic interactions and rotational strengths within protein environment: An electronic structural study on beta-lactamases from class A 78
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 78
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 77
Applications and Advances of QM/MM methods in Computational Enzymology 76
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 76
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 76
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 75
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 75
Catalytic, Asymmetric Hypervinylogous Mukaiyama Aldol Reactions of Extended Furan-Based Silyl Enolates 74
Structure activity relationship of new EphA2 ligands 74
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 74
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. 73
Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents 73
Mechanistic Insights into the Reaction of Chlorination of Tryptophan Catalyzed by Tryptophan 7-Halogenase 72
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 71
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 71
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 71
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 70
On the Use of 2,5-Dimethyl-Pyrrol-1-yl-Benzoic Acid Derivatives as EPH-Ephrin Antagonists. 70
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 69
Therapeutic perspectives of Eph–ephrin system modulation 69
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 69
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 68
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 68
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 68
Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N -(4-Anilinoquinazolin-6-yl) acrylamide 67
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 67
Different roles for the acyl chain and the amine leaving group in the substrate selectivity of N-Acylethanolamine acid amidase 67
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 65
Are we using the right pharmacological tools to target EphA4? 65
Free-energy studies reveal a possible mechanism for oxidation-dependent inhibition of MGL 65
Physical nature of fatty acid amide hydrolase interactions with its inhibitors: Testing a simple nonempirical scoring model 65
Totale 9.317
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.571
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.571
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020471 0 0 0 0 0 0 0 0 185 140 64 82
2020/20211.022 22 79 88 77 125 59 124 43 194 41 88 82
2021/2022850 30 24 24 86 58 28 109 100 58 67 35 231
2022/20233.112 314 309 172 240 288 358 41 196 983 45 127 39
2023/20241.256 82 72 42 43 89 270 118 111 46 64 142 177
2024/20252.527 137 217 271 250 455 481 273 263 180 0 0 0
Totale 12.068